GENENT.046DV1



6/B 1. 5.10.02 PATENT

IN THE UNITED STATES PARENT AND TRADEMARK OFFICE

Applicant	:	Caras et al. #\$) Group Art Unit 1645
Appl. No.	:	10/021,121	I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Filed	:	December 6, 2001	United States Patent and Trademark Office, PO Box 2327, Arlington VA 22202, on
For	:	AL-2 NEUROTROPHIC FACTOR) March 27, 2002 (Date)) Ginger R. Dreger, Reg. No. 33,055
Examiner		Unknown	,

SECOND PRELIMINARY AMENDMENT

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

The present Secondary Preliminary Amendment is submitted for entry in regards to the above-mentioned application, and is necessitated by the submission of formal drawings in response to a Notice to File Corrected Application Papers mailed on February 6, 2002.

Kindly amend this application in the following aspects.

In the Specification:

Please replace the paragraph, beginning at page 5, line 33, with the following rewritten paragraph:

--Figure 1A-1C shows the AL-21-encoding nucleotide sequence (SEQ ID NO: 1), its complementary sequence, and the deduced amino acid sequence of AL-2 of the isolated AL-21 ("AL-2-long") cDNA (SEQ ID NO: 2). The deduced N-terminus of the mature AL-2 protein begins with glycine-27 as numbered from the initiation methionine. The C-terminal hydrophobic